Enemem, Maintenance of analgesia doesn't have to be an all or none phenomenon. If Ampakines prevent RD while maintaining even half the opioid's analgesic effect, we've still got ourselves a big winner, since this would be extremely useful for physicians treating pain with high dose opiates.
Concerning maintenance of analgesia, as Spyderboi pointed out -- the opiate analgesia mechanism is already well understood, and the rodent to human correlation has been well mapped out. The rat to human correlation is much less well established for the RD mechanism, so this is the primary area of uncertainty for these trials.
Greer firmly established that Ampakines reduce opiate RD in rats without affecting analgesia, and we know there's a strong correlation between rat and human analgesia mechanisms. So by far the greatest risk of a failure to translate into humans lies in the RD aspect, not the analgesia aspect.
News 
Market Data 
Discover 
AI
